CytoMed Therapeutics (NASDAQ:GDTC) Trading Down 4.2% – Time to Sell?

Shares of CytoMed Therapeutics Limited (NASDAQ:GDTC) traded down 4.2% on Tuesday . The stock traded as low as $0.9977 and last traded at $1.0160. 4,667 shares were traded during trading, a decline of 42% from the average session volume of 8,037 shares. The stock had previously closed at $1.06.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of CytoMed Therapeutics in a report on Monday, December 29th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company currently has an average rating of “Sell”.

CytoMed Therapeutics Price Performance

The company’s fifty day moving average is $1.02 and its 200 day moving average is $1.51.

CytoMed Therapeutics (NASDAQ:GDTC) last posted its quarterly earnings results on Sunday, February 15th. The company reported ($0.06) EPS for the quarter. The company had revenue of $0.06 million for the quarter.

CytoMed Therapeutics Company Profile

CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. The company is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord derived mesenchymal stem cells for cartilage injury.